Company: BGLC
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001477932-25-002725
Chunk: 316

Company: BioNexus Gene Lab Corp
Filing Date: 2025-04-15
Form: 10-K
Item: Item 12
Chunk 316
---
 EXPENSES  (366,848)  (3,424,310)  (1,144,538)  (4,935,696)                 LOSS FROM OPERATIONS  (235,144)  (194,020)  (1,144,538)  (1,573,702)                 FINANCE COSTS  (11,795)  (9,072)  (279)  (21,146)                 LOSS BEFORE TAX  (246,939)  (203,092)  (1,144,817)  (1,594,848)                 Tax expense:                Deferred tax  -   12,305   -   12,305 Income tax  -   (15,799)  -   (15,799)Tax expense  -   (3,494)  -   (3,494)                 NET LOSS ATTRIBUTABLE TO COMMON SHAREHOLDERS  $(246,939) $(206,586) $(1,144,817) $(1,598,342)    Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Year ended December 31, 2023              Segment assets  $2,522,321  $6,676,344  $2,201,128  $11,399,793                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  247,192   15,486   -   262,678     Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Year ended December 31, 2024              Segment assets  $2,652,754  $6,788,302  $992,792  $10,433,848                  Included in the measure of segment assets are:                 Addition to non-current assets other than financial instruments and deferred tax assets  150,881   221,844   -   372,725   The Company had no inter-segment